
Sedana Medical Q2 - Slower sales ramp-up and new financial targets

Redeye lowers its sales estimates on all time horizons for Sedana Medical following the Q2 report, rendering downward changes to our fair value range. We see a continuous uncertainty in its sales growth prospects in the medium term, further supported by the company's scrapped 2025e sales target, which is replaced by other short-term targets. Still, the US could have significant upside potential if the company successfully manages its EU roll-out.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Sedana Medical Q2 - Slower sales ramp-up and new financial targets